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Brain atrophy inmild cognitive impairment (MCI) andAlzheimer’s disease (AD) are difficult to demarcate to assess the progression
of AD.This study presents a statistical framework on the basis of MRI volumes and neuropsychological scores. A feature selection
technique using backward stepwise linear regression together with linear discriminant analysis is designed to classify cognitive
normal (CN) subjects, early MCI (EMCI), late MCI (LMCI), and AD subjects in an exhaustive two-group classification process.
Results show a dominance of the neuropsychological parameters like MMSE and RAVLT. Cortical volumetric measures of the
temporal, parietal, and cingulate regions are found to be significant classification factors. Moreover, an asymmetrical distribution
of the volumetric measures across hemispheres is seen for CN versus EMCI and EMCI versus AD, showing dominance of the
right hemisphere; whereas CN versus LMCI and EMCI versus LMCI show dominance of the left hemisphere. A 2-fold cross-
validation showed an average accuracy of 93.9%, 90.8%, and 94.5%, for the CN versus AD, CN versus LMCI, and EMCI versus AD,
respectively. The accuracy for groups that are difficult to differentiate like EMCI versus LMCI was 73.6%. With the inclusion of the
neuropsychological scores, a significant improvement (24.59%) was obtained over using MRI measures alone.
1. Introduction
Perhaps one of the most challenging research issues in
Alzheimer’s disease (AD) is in identifying relevant measures
which could define the different stages of AD as a progressive
neurodegenerative disorder [1, 2]. Targeted treatment and
early intervention procedures could be prescribed on the
basis of such findings.
Brain imaging and neuropsychological testing are the
main research domains used to determine specific cogni-
tive, structural, functional, and biological measures to study
AD and its prodromal stages. Structural MRI [3–7] and
functional imaging modalities like Single-Photon Emission
Computed Tomography (SPECT) [8, 9], Positron Emission
Tomography (PET) [10, 11], synchronous neural interactions
(SNI) obtained using magnetoencephalography (MEG) [12,
13], and Central Spinal Fluid (CSF) [6] as well as electroen-
cephalography (EEG) [14–16] have been used with varying
degrees of success in identifying AD. Clinicians regularly use
these biomarkers as guides, and, more recently, combinations
of two or more biomarkers are being explored to improve
our understanding of AD [4–7, 10]. Exemplifying such
combinations, biomarkers of MRI and CSF reportedly yield
better accuracy as compared to their individual results. In
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similar studies, Fan et al. combinedMRI and PET biomarkers
[5], while the group of Walhovd et al. and the group of
Zhang et al. worked on a combination of MRI, PET, and CSF
biomarkers and reported results with conclusive indicators in
the diagnosis of AD or Mild Cognitive Impairment (MCI)
[4, 10].
Many other studies focused on the combination of
neuropsychological testing with medical imaging modalities.
In a notable study, Ewers and his colleagues combined the
main biomarkers of MRI and CSF with neuropsychological
tests to predict the conversion from MCI to AD [17]. Their
study, which included 81 AD patients and 101 elderly control
subjects, demonstrated that single-predictor models do yield
comparable accuracies as multipredictor models. It showed
that when the entorhinal cortex is used as the single predictor,
the accuracy of the results ranged from the mid-60s to a high
of 68.5%. In another study involving the prediction ofMCI to
AD conversion over a 2-year period, Gomar et al. researched
the usefulness of combining different variables drawn from
a series of biomarkers including cognitive markers and the
different risk factors involved [18]. Using brain volumes, CSF
and other cognitive markers, they determined that cognitive
markers at baseline yield better predictors in the conversion
of MCI to AD as compared to temporal neurobiological
markers. They also show that, in contrast to biomarkers, a
sharp decline in functional ability could serve as a better
predictor in the conversion of MCI to AD.This latter finding
concurs with their results that show that, with the inclusion
of neuropsychological data, the accuracy increased to 90% in
delineating AD patients from controls.
Both these studies, which primarily focus on the conver-
sion process of MCI to AD, use a manual selection of the vol-
umetricmeasures of the different regions of the brain and rely
on the ADNI (Alzheimer’s Disease Neuroimaging Initiative)
public database. The proposed study, which relates well to
these two studies, uses instead a fully automated approach to
rank the neurobiological variables and volumetric measures.
Thus, a more global approach is provided for constructing
patterns of structural and physiological abnormalities in their
entirety [5], with statistical proofs in support of the choice of
the different variables and measures considered.
Other studies have focused their research efforts on
determining the distinctive features that could delineate early
MCI (EMCI) from late MCI (LMCI) [19, 20]. For example,
Ferman et al. showed that nonamnestic MCIs (naMCI) were
more likely to develop dementia with Lewy bodies (DLB),
whereas patients with amnestic MCIs (aMCI) are more likely
to convert to AD [21].
The proposed study examines the classification of AD,
EMCI, and LMCI on the basis of a combination of subcortical
and cortical MRI volumes with a slate of neuropsychological
tests that include Mini-Mental State Examination (MMSE),
Rey Auditory Verbal Learning Test (RAVLT), and Clinical
Dementia Rating Scale Sum of Boxes Scores (CDRSb). The
study reveals the importance of including neuropsychological
tests in classifying the different stages of AD by using
a combination of MMSE, RAVLT, and select volumetric
variables. This study proposes also a fully automated feature
extraction technique, with a ranking that provides statistical
significance to the variables to be used in a multidimensional
decisional space for optimal classification.
2. Methodology
Figure 1 illustrates the general structure of the entire process.
The steps include acquisition of the MRI and neuropsycho-
logical parameters, the selection of significant variables using
pairwise backward stepwise linear regression models, and
the classification process using a well-established linear dis-
criminant analysis (LDA). The fully automated data-driven
technique allows for the possibility of replacing LDA with
other algorithms such as Support Vector Machines (SVM)
and Artificial Neural Networks (ANN) and probabilistic
classifiers such as Quadratic Discriminant Analysis (QDA).
2.1. Study Data. Data used in this study were obtained
from the ADNI database (http://adni.loni.usc.edu/). ADNI
launched in 2003 aims to test whether magnetic resonance
imaging, PET, other biological markers, and clinical and
neuropsychological assessment can be combined to measure
the progression of MCI and early AD.
Baseline demographic, clinical, neuropsychological, and
volumetricMRI data for 385 subjects (55 diagnosedwithmild
AD and 91 with LMCI and 114 EMCI and 125 cognitively
normal (CN) cases) were explored as outlined in Table 1.
All subjects had (1) a neurological andmedical evaluation
by a physician; (2) a full battery of neuropsychological tests
[22], all in accordance with the National Alzheimer’s Coor-
dinating Center protocol (http://www.alz.washington.edu/),
along with RAVLT [23]; and (3) structural volumetric MRI
scans of the brain. The CDRSb was used as the index of
functional ability, and the MMSE was used as the index of
cognitive ability.
The cognitive diagnosis was made using a combination of
the physician’s diagnosis and neuropsychological diagnosis,
as described previously [24]. The etiological diagnosis was
made by the examining physician. The diagnosis of CN
required that the physician’s diagnosis was CN and no
cognitive test scores were ≥1.5 SD below age- and education-
corrected means. A probable AD diagnosis required a
dementia syndrome and National Institute of Neurological
and Communicative Disorders and Stroke/Alzheimer’s Dis-
ease and Related Disorders Association criteria for AD [25].
2.2. Imaging Protocol. MRI scans were acquired on a 1.5-T
machine (Siemen’s Symphony, Iselin, NJ, USA, or General
Electric, HDX,Milwaukee,WI, USA) using a proprietary 3D-
magnetization-prepared rapid-acquisition gradient echo (3D
MPRAGE) or 3D spoiled gradient echo sequences (FSPGR).
Specifications for 3DMPRAGE include coronal sections with
a 1.5mm gap in thickness; section interval: 0.75mm; TR:
2190ms; TE: 4.38ms; TI: 1100ms; FA: 15∘; NEX: 1; matrix: 256
× 256; FOV: 260mm; bandwidth: 130Hz/pixel; acquisition
time: 9 minutes; and phase-encoding direction: right to left.
Specifications for 3D FSPGRwere the following: 140 contigu-
ous coronal sections of 1.2mm thickness; contiguous images
with no section interval; TR; 7.8ms; TE: 3.0ms; inversion
recovery preparation time: 450ms; flip angle; 12∘; NEX: 1;
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Figure 1: General construct of the classification study showing the main blocks, namely, image analysis, feature extraction, and classification.
Table 1: Study data characteristics.
Characteristics Cognitive normal (CN) Early MCI (EMCI) Late MCI (LMCI) Alzheimer’s Disease (AD) P value∗
Number of subjects (𝑛) 125 114 91 55
Age (Years) 73.4 ± 5.9 70.7 ± 6.8 71.2 ± 7.8 75.4 ± 8.0 <0.001
Gender (male/female) 58/67 62/52 48/43 32/23 0.442†
Education (years) 16.4 ± 2.5 16.4 ± 2.7 16.6 ± 2.7 16.0 ± 2.4 0.720
CDRSb 0.0 ± 0.1 1.3 ± 0.9 1.9 ± 1.0 4.6 ± 1.6 <0.001
RAVLT 5.7 ± 2.4 5.7 ± 2.5 3.7 ± 2.4 2.0 ± 1.77 <0.001
MMSE 29.06 ± 1.17 28.58 ± 1.48 27.54 ± 1.82 22.80 ± 1.9 <0.001
TIV (mL) 1472.1 ± 148.3 1501.7 ± 148.8 1522.7 ± 163.6 1498.8 ± 169.7 0.123
Unless otherwise noted, data are presented as mean ± S.D.
∗P value based on Student’s 𝑡-test between CN and AD unless otherwise specified and those less than significance level 0.05 are bolded.
†A Fisher’s exact test was performed, and P value shows that gender effect is not significant at significance level of 0.05.
matrix: 256 × 256; FOV: 240mm; bandwidth: 31.25Hz/pixel;
acquisition time: 6-7 minutes; and again phase-encoding
direction: right to left.
2.3. Volumetric Correction. FreeSurfer pipeline (version 5.1.0)
was applied to the MRI scans to produce 115 cortical and
subcortical volumetric variables. These 115 regional volumes
were corrected for head size variation using FreeSurfer’s
estimate of total intracranial volume (TIV), which has been
considered highly accurate in adults [26]. Regional MRI vol-
umes, normalized to total intracranial volume, were obtained
from the ADNI database using data derived by researchers
at the University of California, San Francisco, as part of the
ADNI2 cohort. Each regional volumeof the brainwas divided
by the subject’s TIV to estimate regional volumetric ratios,
which were used as features for the classification models.The
volumes were not corrected for age, gender, and education
since these demographic variables are later used as model
terms in the statistical testing as detailed in Section 2.4.
2.4. Statistical Feature Extraction. Stepwise linear regression
models (SLRM) have been widely used in studies related to
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Figure 2: Procedural steps of the feature extraction technique using SLRM.
Alzheimer’s disease for assessing hippocampal atrophy [27],
functional decline in cognitive ageing [28, 29], and cortical
atrophy [30], to name a few.
In this study, the SLRM method is used as a feature
extraction technique to determine those variables (demo-
graphic, clinical, neuropsychological, or volumetric) that are
significant towards classification of the different subtypes of
the disease. The procedure followed is as shown in Figure 2.
The feature extraction step begins by randomly dividing
the feature set of 120 parameters (age, gender, education, 2
neuropsychological test scores, namely, RAVLT and MMSE,
and 115 corrected volumetric MRI regional ratios) into two
groups. One of these groups is assigned as a training group
and the other is discarded in this initial step. For the training
group pairwise stepwise linear regression models are used to
estimate the best set of parameters, which yields the highest
correlation between the diagnostic gold standard and the
feature set as given in (1).The pairwise models are trained for
each of the six classification pairs, namely, CN versus EMCI,
CN versus LMCI, CN versus AD, EMCI versus LMCI, EMCI
versus AD, and LMCI versus AD. Consider
𝑦 = 𝐶0 +𝐶1 ∗ 𝐹1 +𝐶2 ∗ 𝐹2 + ⋅ ⋅ ⋅ + 𝐶𝑚 ∗ 𝐹𝑚, (1)
where 𝑦 is the model response (a logical variable showing
the class in the pairwise classification pair), 𝐹
1
, 𝐹
2
, . . . , 𝐹
𝑚
are
the 𝑚 feature variables; 𝐶
1
, 𝐶
2
, . . . , 𝐶
𝑚
are their respective
coefficients, and 𝐶
0
is a constant. For the current study
𝑚 = 121; however, the model is completely scalable to
accommodate for fewer or larger number of features if
needed.
The significance threshold for adding a feature to the
model is fixed at 0.1 for the model R2; that is, if the
increase in the R-squared of the model is larger than 0.1, the
corresponding feature is added to the model. On the other
hand, a feature is removed from the model if the feature fails
to improve theR2 of themodel by a number greater than 0.05.
The choice of significant thresholds for adding or removing a
term from the model was empirically adjusted so as to obtain
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a stable model, which can explain the variance in the data.
Stepwise regression models, as executed in the paper, fit an
initial model comprised of a single feature and then grow to
accommodate other features. The choice of an increment in
R2 of 0.1 for adding a parameter to a model was to achieve a
more conservative approach towards limiting feature space.
Complex models with a large number of features often tend
to overfit the model capturing the noise in the data rather
than the underlying phenomenon. The removal threshold
was fixed to 0.05 again to eliminate only weak features that
resulted in lesser than 5% improvement in the model.
To account for the varied nature of the disease and the
random distribution of the data under investigation, the
SLRM are repeated 50 times for each diagnostic pair and only
those features which appear to be significant more than 75%
of the time are retained in the final feature set as was shown
in Figure 2. The final features that are deemed significant are
bound to constitute an optimal decisional space.
2.5. Linear Discriminant Analysis (LDA) Classifier. LDA is a
technique widely used in pattern recognition, statistics, and
machine learning, among others, for determining charac-
teristic features that can aid in difficult segmentation tasks
[31–33]. The LDA classifier used in this study attempts to
estimate a posterior probability for each subject to enable its
classification into either of the two groups for each of the six
pairwise classifications.
The significant features determined in the feature extrac-
tion step are used to train a classifier to estimate the
parameters of the linear discriminant functions for the two
classes as given in
𝑑
𝐿
1 (𝐹1, 𝐹2, . . . , 𝐹𝑚󸀠) = 𝛼1 +𝛼2 ∗ 𝐹1 +𝛼3 ∗ 𝐹2 + ⋅ ⋅ ⋅
+ 𝛼
𝑚
󸀠
+1 ∗ 𝐹𝑚󸀠 ,
𝑑
𝐿
2 (𝐹1, 𝐹2, . . . , 𝐹𝑚󸀠) = 𝛽1 +𝛽2 ∗ 𝐹1 +𝛽3 ∗ 𝐹2 + ⋅ ⋅ ⋅
+ 𝛽
𝑚
󸀠
+1 ∗ 𝐹𝑚󸀠 ,
(2)
where 𝛼
1
, 𝛼
2
, . . . , 𝛼
𝑚
󸀠 and 𝛽
1
, 𝛽
2
, . . . , 𝛽
𝑚
󸀠 are the LDA param-
eters for the two groups, respectively, and 𝐹
1
, 𝐹
2
, . . . , 𝐹
𝑚
󸀠 are
the set of significant parameters for each classification pair,
where𝑚󸀠 ≤ 𝑚.
The training algorithm assumes a prior probability
𝑝prior = 0.5, suggesting that a given subject has an equal
probability of belonging to either one of the two classes. The
classification algorithm assigns posterior probabilities 𝑝
1
or
𝑝
2
on the basis of the linear score 𝐿
1
and 𝐿
2
, respectively, as
described in (3). The posterior probabilities as calculated in
(4) signify the likelihood of a subject to belong to either one
of the groups. A higher posterior probability determines the
grouping of the subjects:
𝐿1 (𝐹1, 𝐹2, . . . , 𝐹𝑚󸀠) = 𝑑
𝐿
1 (𝐹1, 𝐹2, . . . , 𝐹𝑚󸀠)
+ log (𝑝prior) ,
𝐿2 (𝐹1, 𝐹2, . . . , 𝐹𝑚󸀠) = 𝑑
𝐿
2 (𝐹1, 𝐹2, . . . , 𝐹𝑚󸀠)
+ log (𝑝prior)
(3)
𝑝1 =
𝑒
𝐿1(𝐹1 ,𝐹2,...,𝐹𝑚󸀠 )
(𝑒
𝐿1(𝐹1,𝐹2 ,...,𝐹𝑚󸀠 ) + 𝑒
𝐿2(𝐹1 ,𝐹2,...,𝐹𝑚󸀠 ))
,
𝑝2 =
𝑒
𝐿2(𝐹1 ,𝐹2,...,𝐹𝑚󸀠 )
(𝑒
𝐿1(𝐹1,𝐹2 ,...,𝐹𝑚󸀠 ) + 𝑒
𝐿2(𝐹1 ,𝐹2,...,𝐹𝑚󸀠 ))
.
(4)
All of the experiments conducted in this study were based
on 2-fold cross validation, distributing the subjects equally
between training and testing sets. The training and testing
sets were randomly assigned while the number of subjects
in each group remained fixed. To limit the potential data
portioning error introduced by random data assignment and
cross validation, the same experiment with random data
assignment was run 20 times and the average metrics of
accuracy, sensitivity, specificity, precision, and F-measure are
reported.
3. Results and Discussion
3.1. Significant Features. The significant features as deter-
mined by the SLRM technique for each of the six classi-
fications are provided in Table 2. The results show that a
combination, which includes neuropsychological parame-
ters, demographic variables, and the volumetric variables,
could act as the best linear model to estimate diagnostic
patterns in pairwise comparisons. The number of features
that are selected for each pairwise comparison varies from 5
in the case of LMCI versus AD to as many as 14 in the case
of CN versus EMCI. On average, for diagnostic groups which
are closely related to each other in disease progression, that
is, CN versus EMCI, EMCI versus LMCI, and LMCI versus
AD, a fewer number of significant parameters are seen as
compared to groups that are diagnostically well separable.
Such a trend was expected since closely related diagnostic
groups have fewer marked atrophy changes that are visible
with disease progression.
The SLRM offer the opportunity to also rank these vari-
ables on the basis of their significance to each classification
pair. The features listed in Table 2 are ranked according
to the 𝑃 value reflecting the significance of the variable
towards the models. The ranking of the features displays the
potential discriminating power of the different features in
classification of the stages of AD.The anatomical distribution
of the volumetric features, both cortical and subcortical, is
displayed in Figures 3 and 4.
An important observation that can be made from Table 2
is the dominance of the neuropsychological parameters. It is
seen in all the pairwise comparisons that the MMSE appears
at very high ranks. MMSE is ranked as a significant feature in
4 of the 6 pairwise comparisons, whereas RAVLT shows up
as significant in 2 of the 6 pairwise comparisons.
Interesting findings can also be seen in Figures 3 and 4
in terms of asymmetry in the distribution of the volumetric
variables. For example, classification pairs such as CN versus
EMCI and EMCI versus AD show dominance of the right
hemisphere, where most of the significant feature volumes
are from the right hemisphere. On the contrary, CN versus
LMCI and EMCI versus LMCI show dominance of the left
hemisphere. This asymmetrical distribution between groups
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Figure 3: Cortical and subcortical maps showing the significant volumetric regions for each classification pair. (a) CN versus AD, (b) CN
versus EMCI, and (c) CN versus LMCI. The regions are listed in Table 2. For each classification pair the letter “L” or “R” signifies the left and
right hemisphere, respectively. Additionally, for the cortical representations, the top images in each set show the lateral view and the bottom
images show the medial views.
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EMCI versus AD, and (c) LMCI versus AD. The regions are listed in Table 2. For each classification pair the letter “L” or “R” signifies the
left and right hemisphere, respectively. Additionally, for the cortical representations, the top images in each set show the lateral view and the
bottom images show the medial views.
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Table 2: Significant features.
Rank CN versus AD 𝑃 value Rank CN versus EMCI 𝑃 value
1 Left hippocampus volume <0.001 1 Age <0.01
2 Right lateral ventricle volume <0.001 2 Right inferior temporal volume <0.01
3 MMSE <0.001 3 Left thalamus volume <0.05
4 Right pars opercularis volume <0.01 4 Right transverse temporal volume <0.05
5 Age <0.01 5 Right precuneus volume <0.05
6 Education <0.01
7 Fourth ventricle volume <0.05
8 Left choroid plexus volume <0.05
9 Right precentral volume <0.05
10 Whole brain volume <0.05
Rank CN versus LMCI 𝑃 value Rank EMCI versus LMCI 𝑃 value
1 Right hippocampus volume <0.001 1 RAVLT <0.001
2 Left superior parietal volume <0.001 2 Right precuneus volume <0.001
3 MMSE <0.001 3 Left caudal anterior cingulate volume <0.001
4 Age <0.001 4 Left pallidum volume <0.001
5 Left caudal anterior cingulate volume <0.01 5 Left cuneus volume <0.01
6 Left pericalcarine volume <0.01 6 Left middle temporal volume <0.01
7 Right superior parietal volume <0.01 7 Left fusiform volume <0.01
8 Left amygdala volume <0.01 8 Left caudal middle frontal volume <0.05
9 Right lateral occipital volume <0.05 9 Right precentral volume <0.05
10 Left caudate volume <0.05 10 Left thalamus volume <0.05
11 Left transverse temporal volume <0.05
12 Left posterior cingulate volume <0.05
13 Education <0.05
14 RAVLT <0.05
Rank EMCI versus AD 𝑃 value Rank LMCI versus AD 𝑃 value
1 MMSE <0.001 1 Age <0.001
2 Left hippocampus volume <0.001 2 MMSE <0.001
3 Right lateral ventricle volume <0.001 3 Non-WM hypointensities Volume <0.01
4 Right inferior temporal volume <0.001 4 Right pars triangularis volume <0.05
5 Right choroid plexus volume <0.001 5 Left cuneus volume <0.05
6 Right precentral volume <0.001
7 Right paracentral volume <0.01
8 Left caudate volume <0.05
can be a potential indicator of the shifts in atrophy patterns in
the different stages of the disease. In the case of CN versus AD
a more bihemispherical layout of the variables is observed as
was reported in another study [34].
A closer inspection of the results shows that the top
ranked volumetric variables, for example, hippocampus [35–
37], ventricular [38, 39], cortical [35, 37, 40], and amygdala
[39, 41], are all regions that have been proven to be effective
predictors of AD and/orMCI bymany other research groups.
This observation is a strong indicator of the accuracy and
usability of the ranking system developed in this study.
Also, cortical volumetricmeasures of the temporal, parie-
tal, and cingulate regions show a marked presence in the
significant groups. Other recent studies have also demon-
strated the utility of regional temporal brain atrophy [38] and
involvement of frontal lobe atrophy as important markers for
AD staging [42].
3.2. Classification Performance. Figures 5(a)–5(f) show the
classification accuracy, sensitivity, specificity, and precision
for the 6 pairwise comparisons studies in this paper.The study
performs an incremental analysis, whereby the classification
is performed by adding an additional feature to the model
starting with a single feature model. In other words, firstly
only the top variable is used for classification and the
performance is recorded. Following this the top 2 features are
employed in the LDA classifier and so on and so forth. The
results show a typical saturation effect whereby increasing the
number of features in the classifier beyond a point does not
improve the accuracy of the classifier.
Table 3 lists the highest accuracies obtained for each
classification along with the number of features that were
used to yield such accuracies. All results, displayed as Average
± Standard Deviation, indicate that, in all the cases except
in the CN versus AD classification, the highest accuracy
is indeed obtained when all the significant parameters, as
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Figure 5: Results of incremental analysis displaying accuracy, sensitivity, and specificity as a function of the number of features used for the
classifications. (a) CN versus AD, (b) CN versus EMCI, (c) CN versus LMCI, (d) EMCI versus LMCI, (e) EMCI versus AD, and (f) LMCI
versus AD.
enumerated in Table 2, are included in the LDA. In case of
CN versus AD the first seven out of the ten features were able
to define the optimal decisional space for the classification.
Table 3 also highlights the fact that the best classification
accuracies are those obtained for groups, which are well
separated diagnostically. For example, CN versus AD, CN
versus LMCI, andEMCI versusAD show accuracies of 93.9%,
90.8%, and 94.5%, respectively. However, for groups which
are not clearly differentiable like EMCI versus LMCI, an
accuracy of 73.6% was achieved. Although this accuracy
seems to be low, if not better, it is comparable to other studies
found in literature, which have reported a similar accuracy in
classification of MCI subjects [35, 43, 44].
Additionally, the choice of the prior probabilities used
in the classification model can be derived from population’s
empirical estimates; that is, for the classification of AD
subjects from CN the priors for the groups can be chosen to
be 55/180 and 125/180 for theAD andCNgroups, respectively.
Although the choice of empirical prior probabilities may
improve performance, the algorithm refrains from assigning
empirical prior probabilities to reflect the nature of the
problem in clinical environments, where distribution of
subjects can be unknown.
3.3. Impact of Neuropsychological and Volumetric Features.
Results shown in Figure 5 togetherwith those given inTable 4
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Table 3: Optimal accuracy obtained for each classification pair.
Classification Number of features formaximum accuracy Accuracy Sensitivity Specificity Precision 𝐹Measure
CN versus AD 7 0.939 ± 0.012 0.963 ± 0.021 0.895 ± 0.011 0.938 ± 0.026 0.948 ± 0.012
CN versus EMCI 5 0.856 ± 0.023 0.966 ± 0.012 0.741 ± 0.063 0.808 ± 0.062 0.871 ± 0.036
CN versus LMCI 14 0.908 ± 0.031 0.968 ± 0.024 0.837 ± 0.044 0.882 ± 0.054 0.919 ± 0.029
EMCI versus LMCI 10 0.736 ± 0.024 0.743 ± 0.055 0.727 ± 0.061 0.777 ± 0.082 0.758 ± 0.085
EMCI versus AD 8 0.945 ± 0.032 0.946 ± 0.022 0.950 ± 0.023 0.870 ± 0.016 0.951 ± 0.012
LMCI versus AD 5 0.901 ± 0.024 0.907 ± 0.044 0.893 ± 0.012 0.923 ± 0.033 0.914 ± 0.038
Table 4: Accuracy obtained for each classification pair for neuropsychological, MRI, and Combined Model.
Classification Neuropsychological
model MRI measures model Combined model
% Improvement offered
by combined model over
Neuropsychological
model∗
MRI measures
model†
CN versus AD 0.922 0.842 0.939 1.844 11.520
CN versus EMCI 0.846 0.616 0.856 1.182 38.961
CN versus LMCI 0.885 0.714 0.908 2.599 27.171
EMCI versus LMCI 0.634 0.688 0.706 11.356 2.616
EMCI versus AD 0.932 0.814 0.945 1.395 16.093
LMCI versus AD 0.898 0.596 0.901 0.334 51.174
Average 0.853 0.712 0.876 3.118 24.589
∗% Improvement offered by combined model is calculated as (Combined Model/Neuropsychological Model)/Combined Model ∗ 100.
†% Improvement offered by combined model is calculated as (Combined Model/MRI Model)/Combined Model ∗ 1.
clearly illustrate the merits in combining neuropsychological
measures with structural measures, where the combined
model showed much improved accuracies for all the two-
group classifications. For example, inclusion of the third
ranked feature (MMSE) results in a sharp increase in accuracy
in the CN versus AD classification.
In order to assess the merits of each category of these
features, neuropsychological versus MRI measures, the clas-
sification algorithm was modified to operate separately using
only either neuropsychological scores or MRI measures. For
the neuropsychological model all neuropsychological fea-
tures are used in the analysis, whereas in theMRImodel only
all the 115MRImeasures are used as features. In the combined
model all neuropsychological and MRI measures are used
concurrently. Please note that demographic variables, age,
gender, and education, are used in all models as features
to account for variability due to age and gender related
changes often seen in Alzheimer’s disease. Table 4 lists the
average accuracy results obtained using a 2-fold LDAwith 20
repetitions for classification of the different categories using
only neuropsychological scores or MRI measures and then
the combination of both.
It can be seen that the difference between the combined
model and neuropsychological model alone is extremely
small with the combined model offering a relative improve-
ment of only 3.12% on average for the different classification
pairs over a range of (0.33%–11.36%). However, it is interest-
ing to note that the improvement offered by the combined
model in case of EMCI versus LMCI, which are diagnostically
very similar in cognition, is up to 11.36%. Additionally, MRI
models alone offer on average accuracies of 71.2% (60%–
84%). A large improvement in relative accuracy (24.59%) is
thus obtained by combining neuropsychological scores with
the MRI models.
Also, it is seen that for most of the classification pairs the
Neuropsychological model offers a higher accuracy than the
MRI model except for the EMCI versus LMCI classification
pair. This finding shows that cognitive scores are not very
good markers to differentiate between EMCI and LMCI and
in such classification studies MRI based atrophy measures
offer an added advantage.
3.4. Comparative Analysis. A comparison of classification
performancewithmultiple studies that have appeared in liter-
ature is shown in Table 5, providing details of the respective
imaging modality/biomarkers used in the study, the nature
of the dataset used, and the classifier statistics in terms of
the results obtained. The proposed approach achieved a very
good performance relative to these studies. It is seen that for
classification ofAD subjects fromCN the proposed technique
fairs better thanmost of the studies. Another important point
to note is that, except for Cuingnet et al. [36] and Zhou et al.
[34], this study considered a larger database.
Moreover, most of the studies listed do not differentiate
between the EMCI and LMCI groups but are pooled into a
single largerMCI group.The availability of such data from the
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Table 5: Comparison of different methods.
# Authors Classificationgroups
Imaging
modality/biomarkers
Source of data
(Group 1/Group
2)
Repetition
(cross
validation)
Accuracy
(%)
Sensitivity
(%)
Specificity
(%)
1 Zhang et al., 2011[10]
CN, AD MRI ADNI (51/52) 10 (10-fold) 86.2 86.0 86.3
CN, AD CSF ADNI (51/52) 10 (10-fold) 82.1 81.9 82.3
CN, AD PET ADNI (51/52) 10 (10-fold) 86.5 86.3 86.6
CN, AD MRI, PET, CSF ADNI (51/52) 10 (10-fold) 93.2 93.0 93.3
2 Hinrichs et al.,2011 [39]
CN, AD MRI, PET ADNI (48/66) 30 (10-fold) 87.6 78.9 93.8
CN, AD
MRI, PET, CSF,
APOE, cognitive
scores
ADNI (48/66) 30 (10-fold) 92.4 86.7 96.6
3 Magnin et al.,2009 [40] CN, AD MRI Private (16/22) 5000 (4-fold) 94.5 91.5 96.6
4 Klo¨ppel et al.,
2008 [37]
CN, AD MRI (Group I) Private(20/20) LOOCV
‡ 95.0 95.0 95.0
CN, AD MRI (Group II) Private(14/14) LOOCV
‡ 92.9 100.0 85.7
CN, AD MRI (Group III)Private (33/57) LOOCV
‡ 81.1 60.6 93.0
5 Walhovd et al.,2010 [4]
CN, AD MRI ADNI (42/38) N/A 82.5 N/A N/A
CN, AD MRI, CSF ADNI (42/38) N/A 88.8 N/A N/A
6 Cuingnet et al.,
2011 [36]∗
CN, AD MRI ADNI (162/137) N/A (2-fold) N/A 82.0 89.0
CN, AD MRI ADNI (162/137) N/A (2-fold) N/A 68.0 98.0
7 Zhou et al., 2014[34] CN, AD MRI, MMSE Private (129/60) 50 (2-fold) 92.3 88.2 94.2
8 Zhou et al., 2014[41]
CN, AD MRI, MMSE Private (127/59) 50 (2-fold) 92.4 84.0 96.1
CN, aMCI†† MRI, MMSE Private (127/67) 50 (2-fold) 74.9 61.1 83.4
CN, naMCI†† MRI, MMSE Private (127/56) 50 (2-fold) 74.1 55.2 82.3
9 Desikan et al.,
2009 [45]
CN, MCI§ MRI OASIS† (48/49) N/A 84.0 73.0 94.0
CN, MCI§ MRI ADNI (57/94) N/A 88.9 90.0 91.0
10 Davatzikos et al.,2008 [46] CN, MCI
§ MRI BLAS∗∗ (15/15) N/A 90.0 N/A N/A
11 Fan et al., 2008[47]
CN, AD MRI, MMSE ADNI (56/66) LOOCV‡ 94.3 N/A N/A
CN, MCI§ MRI, MMSE ADNI (56/88) LOOCV‡ 81.8 N/A N/A
AD, MCI§ MRI, MMSE ADNI (66/88) LOOCV‡ 74.3 N/A N/A
12 Fan et al., 2008[5]
CN, MCI§ MRI, PET BLAS∗∗ (15/15) LOOCV‡ 90.0 N/A N/A
CN, MCI§ MRI BLAS∗∗ (15/15) LOOCV‡ 87.0 N/A N/A
CN, MCI§ PET BLAS∗∗ (15/15) LOOCV‡ 50.0 N/A N/A
13 Proposed Study
CN, AD MRI, cognitivescores ADNI 2 (125/55) 20 (2-fold) 93.9 96.3 89.5
CN, EMCI MRI, cognitivescores ADNI 2 (125/114) 20 (2-fold) 85.6 96.6 74.1
CN, LMCI MRI, cognitivescores ADNI 2 (125/91) 20 (2-fold) 90.8 96.8 83.7
∗This paper by Cuingnet et al. [36] compares ten methods and results of methods with best sensitivity and specificity are shown here since accuracy is not
reported.
†Oasis stands for Open Access Series of Imaging Studies (OASIS) database.
§The fraction Group 1/Group 2 lists the number of subjects in each classification group.
‡LOOCV: Leave one out cross validation.
∗∗BLAS: Baltimore Longitudinal Study of Aging.
††aMCI and naMCI represent amnestic and nonamnestic MCI, respectively.
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ADNI2 cohort made it possible for this study to explore this
specific two-group classification and evaluate their distinctive
features in the progression stages of AD.
The study by Klo¨ppel et al. [37] shows the best results
of all studies that only use MRI imaging based markers.
For this study diagnosis of patients in Group I and Group
II is confirmed using either histopathologically or neu-
ropathologically with the aid of a biopsy or autopsy. Such a
method of validation is extremely useful andmost reliable for
providing a more definite diagnosis that is less susceptible to
errors caused by the subjectivity of the physician’s diagnosis.
Diagnosis in living subjects like those included in the pro-
posed study naturally tends to be more subjective in nature.
However, this does not hinder the intent or the merit of this
study, which is to achieve high classification accuracy on a
large population group with ease of applicability in a clinical
setting.
Another important feature that can be observed from
Table 5 is the comparative performance of the proposed study
to multimodal imaging studies. It is shown that the classi-
fication performance achieved in this study is competitive
and sometimes even better than other studies that relied
on multiple imaging modalities. Although combination of
modalities like PET and CSF provides valuable insight into
the disease, their lack of availability across imaging centers
and medical institutions hinder their potential integration in
the decision making process in such facilities. A significant
merit of the proposed technique is in its ability to achieve
a very good classification performance using only MRI
modality in conjunction with neuropsychological scores, all
of which are routinely carried out for the diagnosis of AD.
The main limitation of this study was that the diagnosis
of MCI and AD and the distinction of these two entities
from normal aging are based on clinical measures, of which
memory measures are paramount. On the other hand,
structural MRI, as used in this study, measures volumetric
changes in the brain. The severity of Alzheimer’s pathology
is only weakly correlated to cognitive and functional changes
during life (in part because several other variables such as
age and cognitive and brain reserve capacity can modify
the correlations), but the pathology is strongly correlated
to volumetric MRI changes. Furthermore, about 30−40% of
cognitively normal elderly individuals have the pathology of
Alzheimer’s disease in their brains and these changes will
be reflected as volumetric changes in their MRI scans, but
not in their cognitive measures. Hence, using MRI measures,
there is considerable overlap built in between “normal aging”
and MCI/AD and so the classification between CN and
MCI/AD is automatically at a disadvantage as compared
to cognitive measures. It is, therefore, not surprising that
we found MRI measures to provide only a small additional
effect in separating CN from MCI/AD. A major advantage
to using structural MRI scans is in distinguishing between
different causes of dementia, such as separating the signature
or atrophy patterns in Alzheimer’s disease from frontotem-
poral dementia, vascular dementia and hydrocephalus, and
distinguishing subtypes of Alzheimer’s disease by the pattern
of atrophy. These issues were not addressed as they were
beyond the scope of this study, in which we addressed only
the magnitude of contribution of volumetric MRI measures
to the cognitive measures.
4. Conclusions
This study introduced a novel framework that combined
MRI volumetric measures with neuropsychological scores in
a statistically meaningful way. Consequently, a ranking of
these features, structural and cognitive, proved very useful in
constructing optimal decisional spaces for high-accuracy in
two-group classifications. The highly ranked MRI measures
proved effective in extracting the significant brain atrophy
regions associated with AD and its prodromal stages for
classifying cognitive normal subjects, EMCI, LMCI, and AD
subjects.The feature extraction technique is based on a back-
ward stepwise linear regression analysis, which demonstrated
dominance of neuropsychological parameters like MMSE
and RAVLT in delineating the different groups.The extracted
features are also dominated by the presence of well-known
subcortical atrophy regions like the hippocampus, amygdala,
and ventricles and various temporoparietal and cingulate
cortical regions. Classification results in two-group compar-
isons revealed a very high accuracy of 93.9%, 85.6%, 90.8%,
73.6%, 94.5%, and 90.1% for CN versus AD, CN versus EMCI,
CN versus LMCI, EMCI versus LMCI, EMCI versus AD,
and LMCI versus AD, respectively. The study also showed
that a combination of MRImeasures and neuropsychological
parameters do yield better diagnostic results on average
(accuracy: 87.6%) than using either MRI (accuracy: 71.2%)
or cognitive scores (accuracy: 85.3%) alone. A practical merit
of the proposed technique is in its ability to achieve high
classification accuracy using only the MRI modality together
with neuropsychological scores, all of which are routinely
carried out for diagnosing AD.
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